NAV

CoronaVac

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
CoronaVac
DrugBank Accession Number
DB15806
Background

CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation2. It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone1,2. In preclinical trials, PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in rats, mice, and the rhesus macaque. The antibodies were found to neutralize 10 representative SARS-CoV-2 strains. As of August 2020, the vaccine is being tested in numerous human clinical trials assessing its safety and immunogenicity.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
  • PiCoVacc
External IDs
  • CoronaVac

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
M1QXB372B8
CAS number
Not Available

References

General References
  1. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C: Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6. [Article]
  2. Rego GNA, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, Mamani JB, Gamarra LF: Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2. Vaccines (Basel). 2020 Aug 25;8(3). pii: vaccines8030474. doi: 10.3390/vaccines8030474. [Article]
  3. Sinovac Announcement [Link]
  4. Vaccine in Rheus Monkeys [Link]
Wikipedia
CoronaVac

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingHealth Services ResearchAdverse Reaction to Vaccine / Coronavirus (SARS-CoV) / Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus1
4Active Not RecruitingPreventionAcquired Immune Deficiency Syndrome (AIDS) / Coronavirus Disease 2019 (COVID‑19) / Human Immunodeficiency Virus (HIV) Infections / Immunogenicity / Rheumatic Diseases / Safety Issues1
4Active Not RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)5
4Active Not RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / COVID19 Vaccination1
4Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
4CompletedPreventionCoronavirus Disease 2019 (COVID‑19)3
4Not Yet RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)1
4RecruitingPreventionChronic Liver Diseases (CLD) / Coronavirus Disease 2019 (COVID‑19)1
4RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)6
4RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / Pulmonary Tuberculosis (TB)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at September 05, 2020 17:17 / Updated at September 14, 2020 17:36